NYSE$PM
Philip Morris International Inc. · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Philip Morris International's financial performance was marked by growth in smoke-free products and strategic acquisitions.
Philip Morris International (PMI) reported its Q4 and Full Year 2022 results, demonstrating growth in key areas despite a challenging operating environment. The company's focus on smoke-free products is paying off, with this category now accounting for a significant portion of total net revenues. Strategic acquisitions, such as Swedish Match, are expected to further drive the company's transformation.
- Total shipment volume increased by 1.2%, driven by a 26.1% increase in HTU shipments.
- Net revenues from smoke-free products accounted for 36.0% of total net revenues.
- Total IQOS users at quarter-end estimated at approximately 24.9 million.
- PMI announced a long-term collaboration with KT&G to commercialize KT&G’s innovative smoke-free devices and consumables on an exclusive, worldwide basis (excluding South Korea).
Headline financials
Revenue & EPS history
Philip Morris · Revenue · Quarterly
$8.15B
Revenue by segment
Philip Morris · $5.61B total across 1 segment · Q3 2022
- Combustible Products$5.61B-3.2%100.0%
Forward guidance
PMI forecasts for the full year 2023, including an expected organic top-line growth and currency-neutral adjusted diluted EPS growth, despite inflationary pressures and transitory impacts related to ILUMA deployment.
Tailwinds
- Organic top-line growth of 7% to 8.5%.
- Currency-neutral adjusted diluted EPS growth of 7% to 9%.
- Continued strong growth from Swedish Match’s existing operations, underpinned by strong shipment volume growth for ZYN in the U.S.
- HTU shipment volume of 125 to 130 billion units, reflecting an acceleration in growth versus 2022 on a total PMI basis.
- Wellness and Healthcare segment net revenues of around $300 million.
Headwinds
- Continued global inflationary pressures, primarily impacting cost of sales for the combustible tobacco business.
- The continued transitory impacts associated with the ILUMA roll-out, including the margin impact of accelerated device replacements and higher initial costs of devices and consumables.
- Incremental investments to drive future growth, including the commercialization of ILUMA and around $150 million with a broadly even split between the U.S. and the wellness and healthcare segment.
- Adjusted operating income margin decline of 50 to 150 basis points on an organic basis.
- Wellness and Healthcare segment with an adjusted operating loss of around $150 million, primarily due to investments in research and development.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+0.8%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+2.2%
Avg return
30 days after
55%
40 / 73 earnings
Positive
+10.9%
Q4 2024
Best reaction
-16.9%
Q1 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.5% | +5.0% | +23.5% | |
| Q4 2025 | +0.4% | +2.3% | -6.6% | |
| Q3 2025 | -4.0% | -0.3% | -1.5% | |
| Q2 2025 | -0.4% | +1.7% | +0.1% | |
| Q1 2025 | +2.3% | +3.1% | +8.6% | |
| Q4 2024 | +10.9% | +13.0% | +15.2% | |
| Q3 2024 | +10.5% | +9.2% | +10.3% | |
| Q2 2024 | +3.9% | +5.7% | +12.0% | |
| Q1 2024 | +5.3% | +1.0% | +5.9% | |
| Q4 2023 | -2.5% | -2.5% | +1.4% | |
| Q3 2023 | -0.7% | -2.6% | -1.4% | |
| Q2 2023 | -1.3% | -1.6% | -4.5% | |
| Q1 2023 | -3.7% | -2.8% | -8.2% | |
| Q4 2022 | +1.1% | +0.4% | -2.9% | |
| Q3 2022 | +0.0% | +2.3% | +11.3% | |
| Q2 2022 | +6.8% | +7.5% | +11.5% | |
| Q1 2022 | -0.3% | -0.3% | -1.8% | |
| Q4 2021 | +3.7% | +5.4% | -14.6% | |
| Q3 2021 | -0.4% | -0.6% | -6.1% | |
| Q2 2021 | -1.4% | +0.5% | +3.6% | |
| Q1 2021 | +2.7% | +3.2% | +6.3% | |
| Q4 2020 | +5.0% | +6.7% | +7.4% | |
| Q3 2020 | -5.2% | -4.4% | -0.4% | |
| Q2 2020 | +4.3% | +5.4% | +7.3% | |
| Q1 2020 | -4.9% | -4.2% | -8.3% | |
| Q4 2019 | +4.2% | +6.6% | +4.0% | |
| Q3 2019 | +1.8% | +2.6% | +7.2% | |
| Q2 2019 | +9.5% | +7.0% | +4.8% | |
| Q1 2019 | -1.4% | -0.7% | +1.6% | |
| Q4 2018 | +5.9% | +6.7% | +15.8% | |
| Q3 2018 | +5.0% | +4.7% | +2.1% | |
| Q2 2018 | +2.6% | +1.7% | +3.5% | |
| Q1 2018 | -16.9% | -18.7% | -20.4% | |
| Q4 2017 | +1.1% | +4.2% | +9.5% | |
| Q3 2017 | -2.7% | -3.5% | -8.8% | |
| Q2 2017 | -1.7% | -3.1% | -5.2% | |
| Q1 2017 | -3.8% | -0.7% | +0.7% | |
| Q4 2016 | +5.4% | +5.9% | +14.9% | |
| Q3 2016 | +0.5% | +0.8% | -6.5% | |
| Q2 2016 | -3.3% | -3.1% | -2.6% | |
| Q1 2016 | -2.5% | — | — | |
| Q4 2015 | -0.3% | — | — | |
| Q3 2015 | +3.9% | — | — | |
| Q2 2015 | +3.8% | — | — | |
| Q1 2015 | +9.1% | — | — | |
| Q4 2014 | -1.0% | — | — | |
| Q3 2014 | +2.9% | — | — | |
| Q2 2014 | +1.6% | — | — | |
| Q1 2014 | -1.5% | — | — | |
| Q4 2013 | +4.4% | — | — | |
| Q3 2013 | +1.0% | — | — | |
| Q2 2013 | -1.2% | — | — | |
| Q1 2013 | -2.2% | — | — | |
| Q4 2012 | +3.1% | — | — | |
| Q3 2012 | -4.1% | — | — | |
| Q2 2012 | -0.6% | — | — | |
| Q1 2012 | +0.1% | — | — | |
| Q4 2011 | +1.1% | — | — | |
| Q3 2011 | +0.5% | — | — | |
| Q2 2011 | -1.7% | — | — | |
| Q1 2011 | -1.2% | — | — | |
| Q4 2010 | +0.8% | — | — | |
| Q4 2007 | +0.8% | — | — | |
| Q3 2010 | -1.0% | — | — | |
| Q2 2010 | +0.7% | — | — | |
| Q1 2009 | +0.7% | — | — | |
| Q1 2010 | -0.0% | — | — | |
| Q4 2009 | -1.4% | — | — | |
| Q3 2008 | +2.5% | — | — | |
| Q3 2009 | +2.5% | — | — | |
| Q2 2009 | -2.1% | — | — | |
| Q2 2008 | -2.1% | — | — | |
| Q4 2008 | -2.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro